We are delighted to announce a new collaboration with Flagship Pioneering and Cambridge University Health Partners (CUHP), to jointly advance breakthrough scientific research and technologies.
The collaboration will focus on research and innovation and will enable Flagship Pioneering’s ecosystem of more than 40 companies to partner with the Milner Therapeutics Institute and CUHP to access breakthrough science and technologies, clinical translation and trial support, and data assets and biosamples.
Through this new partnership, Flagship will gain access to exciting opportunities across other top organizations in the Cambridge life sciences ecosystem, including the Wellcome Sanger Institute, the MRC Laboratory of Molecular Biology, the Babraham Institute, University of Cambridge, the NIHR Cambridge Biomedical Research Centre, the NIHR Cambridge Clinical Research Facility, and the Cambridge University Hospitals NHS Trust.
Research collaborations like this can further propel the UK’s position as a hub for biotechnology innovation. We are pleased to add Flagship’s unique approach to company creation and development to the thriving ecosystem that exists here in Cambridge, and look forward to seeing where the collaboration will lead.
We are excited to work with Flagship Pioneering to develop big ideas in the life sciences together with other Cambridge researchers.
About the partners
Flagship Pioneering invents and builds bioplatform companies, each with the potential for multiple products that transform human health or sustainability. Since its launch in 2000, Flagship has originated and fostered more than 100 scientific ventures, resulting in more than $60 billion in aggregate value. Flagship is operating with $14 billion of assets under management as of its latest capital raise, announced in July 2024. The current Flagship ecosystem comprises over 40 companies, including Foghorn Therapeutics (NASDAQ: FHTX), Moderna (NASDAQ: MRNA), Omega Therapeutics (NASDAQ: OMGA), Sana Biotechnology (NASDAQ: SANA), Generate Biomedicines, Inari, Indigo Agriculture, and Tessera Therapeutics.
Cambridge University Health Partners (CUHP) is one of eight Academic Health Science Centres in England, whose mission is to improve patient healthcare by bringing together the NHS, industry and academia. Along with leaders from across the Cambridge life sciences and healthcare ecosystem, CUHP devised and now implements the life science strategy for the Cambridge cluster. The partners are Anglia Ruskin University (ARU), Cambridge and Peterborough NHS Foundation Trust, Cambridge University Hospitals NHS Foundation Trust, Royal Papworth Hospital NHS Foundation Trust and the University of Cambridge.
The Milner Therapeutics Institute (MTI) is a purpose-built research institute at the University of Cambridge, with an overarching vision to convert pioneering science into therapies by driving academic-industry partnerships. The MTI demonstrates a world-leading model of start-up companies, academics and pharma working side by side.
The MTI has an in-house research programme that has built a mass of expertise in computational research and functional genomics, and is the headquarters of the Milner Therapeutics Consortium, a partnership of nine pharma companies and three academic institutions that provides routes to engage with Cambridge academics and entrepreneurs. The MTI also provides space for start-ups through the Frame Shift Bio-incubator.
